Patent intelligence · US
US 9770414
Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
Patent details — US 9770414
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 26, 2017
- Expiration
- Sep 21, 2037
- Applicant
- Pacira Pharmaceuticals, Inc.
- Claims
- 65
- CPC classes
- A61K, A61K31/198, A61K31/25, A61K31/519
Quick answer
US 9770414 (Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Sep 26, 2017. Expires Sep 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Pacira Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 65
- CPC classes
- A61K, A61K31/198, A61K31/25, A61K31/519, A61K31/575, A61K31/685
More from Pacira Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12370142
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12364764
Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same
granted -
US 12318483
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12296047
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12285435
Multivesicular liposome formulations of dexamethasone
granted -
US 12285419
Bupivacaine multivesicular liposome formulations and uses thereof
granted -
US 12280149
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12251472
Manufacturing of bupivacaine multivesicular liposomes
granted
Frequently asked questions
What is US patent 9770414?
US 9770414 (Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Sep 26, 2017. Expires Sep 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9770414?
Pacira Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 9770414 expire?
Our index shows an expiration date of Sep 21, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.